These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 30130979)

  • 41. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
    Coons JC; Albert L; Bejjani A; Iasella CJ
    Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
    Lucijanic M; Jurin I; Jurin H; Lucijanic T; Starcevic B; Skelin M; Glasnovic A; Catic J; Jurisic A; Hadzibegovic I
    Int J Cardiol; 2020 Feb; 301():90-95. PubMed ID: 31748190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
    Amin A; Garcia Reeves AB; Li X; Dhamane A; Luo X; Di Fusco M; Nadkarni A; Friend K; Rosenblatt L; Mardekian J; Pan X; Yuce H; Keshishian A
    PLoS One; 2019; 14(3):e0213614. PubMed ID: 30908512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.
    Briasoulis A; Mentias A; Mazur A; Alvarez P; Leira EC; Vaughan Sarrazin MS
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):261-272. PubMed ID: 33404923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
    Harel Z; McArthur E; Jeyakumar N; Sood MM; Garg AX; Silver SA; Dorian P; Blum D; Beaubien-Souligny W; Yan AT; Badve SV; Smyth B; Jun M; Jandoc R; Kitchlu A; Wald R
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1470-1479. PubMed ID: 34407990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
    Ganetsky M
    J Emerg Med; 2015 Nov; 49(5):693-7. PubMed ID: 26149803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
    Pasciolla S; Zizza LF; Le T; Wright K
    Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
    Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
    PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
    Brodie MM; Newman JC; Smith T; Rockey DC
    Am J Med; 2018 May; 131(5):573.e9-573.e15. PubMed ID: 29175237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
    Yang L; Brooks MM; Glynn NW; Zhang Y; Saba S; Hernandez I
    Am J Cardiol; 2020 Jul; 126():29-36. PubMed ID: 32359718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.